Abstract
Artificial intelligence (AI) is certainly not a panacea for solving the ‘Pharma Dilemma’, in which the cost of producing new drugs continues to spiral. However, AI can be used to fundamentally change the way we perform essential steps in clinical trial design and execution, from cohort selection to patient monitoring. Merging AI and clinical expertise across engineering and medical disciplines to explore the impact of these changes on trial performance and success rates is one of the most promising leads we have for restoring efficiency and sustainability to the drug development cycle.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.